A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
A training split refers to how the trainee divides and schedules their training volume, or in other words which muscles are trained on a given day over a period of time (usually a week). Popular training splits include full body, upper/lower, push/pull/legs, and the "bro" split. Some training programs may alternate splits weekly.
In the 1984 presidential election, SPUSA nominated the Citizens Party candidate for president, Sonia Johnson. In the 2020 presidential election, the SPUSA nominated the Green Party nominee Howie Hawkins for president. Hawkins also received various state-level party endorsements, such as the Liberty Union Party in Vermont, in a bid to unite the "non-sectarian independent Left" behind a single campaign.
== See also == Antioxidant – Compound that inhibits the oxidation of other molecules Advanced glycation endproduct – Proteins or lipids chemically altered by sugar exposurePages displaying short descriptions of redirect targets
=== Gastrointestinal dynamics === The most common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. These gastrointestinal effects are dose-dependent and mostly mild-to-moderate in severity. They are highly transient, typically peaking during the initial 8-to-12-week dose-escalation phase before waning over time. The drug delays gastric emptying, which can lead to indigestion, belching, and rarely, gastroparesis or bowel obstruction.
Sources: en.wikipedia.org
== External links == "Food Packaging -- Roles, Materials, and Environmental Issues - IFT.org". www.ift.org. Retrieved 3 December 2018. Poly(hydroxyalkanoates) for Food Packaging: Application and Attempts towards Implementation
Hinduism is the majority faith followed by nearly 80% of the population; Islam is the largest minority at over 14%. India also has populations of Christians and Sikhs in the tens of millions, Buddhists and Jains fewer than 10 million, and historical populations of Zoroastrians in the tens of thousands and Jews less than ten thousand. As of the 2011 census, India's last census, Hindus comprised a majority in 28 of India’s 35 states and union territories; this included the four most populous states: Uttar Pradesh (total population: 200 million; Hindu population: 80% of the state's total), Maharashtra (112 million, 80%), Bihar (104 million, 83%) and West Bengal (91 million, 71%). Muslims are in the majority in Lakshadweep Islands (60,000, 97%) and Jammu and Kashmir (8.6 million, 68%). Indian Christians make up about 2.3% of India's population. Saint Thomas Christians number around 8.7 million, whereas Indian Catholics number 11.8 million. Nearly 33% of Adivasi (or Scheduled Tribes of India's Constitution) are Christian. They are concentrated in three hill states of the northeast, Mizoram, Meghalaya, and Nagaland, where they constitute between 70% and 90% of the population. As per the 2011 census, Sikhs comprised less than 2% of India's population, though they were a majority in Punjab state, where more than 87% of Sikhs were farmers. Indian Buddhists number 8.45 million, with 77%, or 6.5 million, living in the state of Maharashtra. Indian Jains number 4.45 million, and Zoroastrians (Parsis), 60,000. As of 2019, there were 3,000 Jews in India, down from 28,000 in 1950.
What are the basic building blocks of emotional life? Why is it that people quickly and effortlessly perceive anger, sadness, fear in themselves and others, yet scientists have been unable to specify a set of clear criteria for empirically identifying these emotional events? What roles do language and conceptual knowledge play in emotion perception Are there really differences between the emotional lives of men and women (see Sex differences in psychology § Emotion)
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.